Groundbreaking Clinical Trial Data for BellaSeno's Technology Unveiled
Revolutionary Data from BellaSeno's Clinical Trials
At the 93rd Annual Plastic Surgery Meeting, BellaSeno GmbH presented promising data from their landmark study on scaffold-guided breast regeneration. This innovative approach showcases a statistically significant advantage over traditional fat grafting methods, boasting twice as high breast volume retention.
Study Overview: Safety and Performance
The clinical trial, spearheaded by Principal Investigator Professor Owen Ung, focused on the application of BellaSeno's 3D-printed resorbable breast scaffolds. The research, currently registered under ClinicalTrials.gov ID NCT05437757, aligns with BellaSeno's mission to enhance safety in breast reconstructive procedures. Results revealed that the company's scaffolds not only proved safe but also boosted patient satisfaction and overall well-being.
Significant Findings and Patient Outcomes
In this open-label, single-arm trial, 19 participants underwent breast implant revision surgery, where existing silicone implants were replaced with biodegradable scaffolds. Approximately half of the volume was filled with the patient’s own fat graft. Initial outcomes looked promising, as thirteen patients completed a 12-month follow-up and demonstrated no complications like explantation or infections, which are often associated with silicone implants.
Enhanced Volume Retention
One of the key findings from the first set of results indicated that the BellaSeno mPCL scaffolds allowed for 80% volume retention compared to only 60% from standard autologous fat grafts. Additionally, MRI imaging 12 months post-surgery confirmed excellent soft tissue retention, while patients reported substantial improvements in breast satisfaction and well-being.
Potential for Future Trials
Professor Owen Ung expressed enthusiasm regarding the results, highlighting the prospect of protected autologous reconstruction (PAR) as a revolutionary procedure for women seeking breast implant revision or reconstruction. The goal is to expand this study phase into an international multi-center trial, offering the transformative benefits of this innovative technology to a broader patient population worldwide.
Addressing Challenges of Traditional Procedures
Traditional breast augmentation and reconstruction rely heavily on silicone implants, which may lead to complications, including capsular contracture and ruptures. BellaSeno's approach using their resorbable scaffold, coupled with an autologous fat graft, provides a strategic alternative. Over time, these scaffolds naturally assimilate into bodily tissue, promoting safer outcomes while potentially catering to a wide array of applications, from aesthetic surgeries to interventions following mastectomy.
Building on Previous Research
This clinical trial is an extension of BellaSeno's prior successful studies, including the first-in-human trial for correcting pectus excavatum, based on the same scaffold technology—a study that received EU Market Authorization in the previous year. The ongoing research aims to thoroughly assess the long-term safety and efficacy of the mPCL scaffolds ahead of the anticipated conclusion results in the years to come.
About BellaSeno
BellaSeno GmbH is an innovative leader in the development of resorbable soft tissue and bone reconstruction implants utilizing advanced additive manufacturing techniques. Founded in 2015 and situated on the BioCity campus in Leipzig, Germany, the company holds ISO 13485 certification and has established a subsidiary in Australia. BellaSeno has garnered significant support from various investors, including governmental entities, facilitating their groundbreaking work in tissue engineering.
Contact Information
BellaSeno GmbH
Dr. Mohit Chhaya
Email: mohit.chhaya@bellaseno.com
Phone: +49 176 2283 9583
Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
Email: info@akampion.com
Tel: +49 40 88 16 59 64
Tel: +49 30 23 63 27 68
Frequently Asked Questions
What is the primary focus of BellaSeno's clinical trial?
The clinical trial primarily focuses on assessing the safety and performance of BellaSeno's resorbable breast scaffolds in patients undergoing breast implant revision.
How does BellaSeno's technology compare to traditional methods?
BellaSeno's technology offers significantly better volume retention and reduced complication rates compared to traditional silicone implants and fat grafting methods.
What are the expected outcomes from the ongoing study?
The expected outcomes include long-term data on the safety, performance, and patient satisfaction relating to the use of mPCL scaffolds in breast surgeries.
Who leads the clinical trial?
Professor Owen Ung serves as the principal investigator, guiding the study aimed at breast reconstruction techniques.
What future plans does BellaSeno have for its research?
BellaSeno aims to expand its clinical trials into international multi-center studies to further validate the effectiveness of their innovative technology.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Top Dividend Stocks to Consider for Strong Returns Now
- Growth Forecast for Cellulose Nanofibrils Market to 2034
- Blabberix Launches Token Presale, A Game Changer for Web3
- Dentsply Sirona's Q3 Conference Call Set for November Announcement
- Sotherly Hotels Inc. Prepares for Third Quarter Financial Results
- Netcracker Achieves Prestigious Award for Satellite Innovation
- Schrödinger to Showcase Innovative Preclinical Data at Upcoming Symposium
- Premia Partners Unveils Innovative Taiwan 50 ETF for Investors
- Premia Partners Unveils Taiwan 50 ETF for Investors
- Groundbreaking Study Explores Girls' Barriers in STEM Fields
Recent Articles
- Hybrid Power Systems Set for Major Growth in Coming Years
- Online Therapy Market Growth Expected to Reach $24.80B
- VEON Unveils KINOM: A Groundbreaking Digital Platform
- BlackRock's Increasing Stake in Endeavour Mining Explained
- InterDigital and Lenovo Team Up for Innovative Licensing Deal
- RE-ZIP Partners with Amazon for Innovative Sustainability Trial
- Exploring the Impact and Future of RCS Messaging Technology
- Expert Lawyers Alan Cunningham and Richard Skipper Now at Hunton Andrews Kurth
- InterDigital and Lenovo Launch New Licensing Agreement Strategy
- Celonis Welcomes Mannu Lodha as Vice President for Nordics
- VEON Launches Innovative KINOM Streaming Service in Uzbekistan
- General Motors Unveils Budget-Friendly Silverado EV Trims
- Rise in Condominium Listings as Sellers React to Market Trends
- BioCorteX's Innovative Insights Transform Cancer Treatment Paradigm
- Dunelm Partners with Google Cloud to Revolutionize Online Shopping
- Empowering Cybersecurity: Happiest Minds Launches Secureline360
- OnBuy Partners with Google Cloud for Global Marketplace Growth
- Markel Expands Cyber Underwriting Team with New Hire
- Markel Strengthens Cyber Underwriting Team with New Hire
- Incubeta Enhances Business Efficiency with AI Integration
- JPMorgan's Upgrade of Inter & Co: A 40% EPS Growth Ahead
- Truist Adjusts Merck's Stock Target Amid Acquisition Insights
- Affirm Holdings: Leveraging Interest Rate Cuts for Growth
- Fosun Strengthens Its Presence in the Middle East Market
- Fosun's Strategic Ventures Drive Growth in Emerging Markets
- Positive Outlook for SBI Stock Despite Recent Downgrade
- UBS Optimistic on Judo Capital's Future Growth Prospects
- JMP Securities Optimizes Raymond James Stock Rating Outlook
- US Futures Dip as DOJ Considers Google Break-Up, Rio Tinto's Move
- European Stock Market Gains Driven by Defensive Sectors
- The Impact of EU-China Trade Tensions on Global Markets
- Understanding Currency Debasement and Its Consequences
- Lifeboat Market Growth Drivers & Future Projections 2024-2033
- Growing Demand in Atorvastatin Calcium Market to $487.8M
- Eckoh Plc's Market Activity and Regulatory Compliance Update
- Enhancing Employee Satisfaction with Dial A Vet Services
- Palantir's Shyam Sankar Discusses AI's Experiential Nature and Value
- DOJ Weighs Breakup of Google Over Antitrust Concerns
- Alpha Fusion Secures Series B Funding to Boost Drug Research
- Curve Therapeutics Welcomes Rab Prinjha to Leadership Team
- Inghams Group Ltd: Steady Poultry Producer Navigates Challenges
- RBC Capital Optimistic About Domino's Future and Growth
- 42com Expands its Telecom Services in Italy with New Offerings
- Redburn Upgrades MSCI Inc. Stock, Predicts Bright Future Ahead
- Antag Therapeutics Progresses Obesity Treatment with FDA Approval
- Redburn Sees 30% Upside for London Stock Exchange Group
- Berenberg Boosts Subsea 7 Outlook Amid Offshore Capex Growth
- CLSA Upgrades Mahindra Stock on SUV Growth and Strong Margins
- Nomura's Optimistic Outlook for Nippon Life India Stock Growth
- Morgan Stanley Sees Potential in Affirm's Customer Expansion